Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← Analysis & Perspectives
MillimanOctober 22, 2026

340B Drug Pricing Reform Could Ripple Into Medicaid Drug Pricing Dynamics

Milliman's white paper examines the rapid growth of the 340B Drug Pricing Program and CMS's proposed CY2027 OPPS rule to cut Medicare Part B 340B drug payments, noting the program's deep interconnection with Medicaid Best Price requirements and Medicare Maximum Fair Price policy. While the analysis is primarily focused on Medicare outpatient reimbursement and hospital financial impacts, it flags downstream effects relevant to drug pricing stakeholders broadly, including those managing Medicaid pharmacy benefit and rebate calculations. Medicaid managed care plans with pharmacy benefit responsibilities may need to track these reforms given the programs' interlocking statutory ceiling price mechanics.

Pharmacy · Finance

Read the full analysis at Milliman →

This is outside commentary from Milliman, not part of Medicaid Monitor's independently scored news coverage.

Share this

More from Milliman

← Analysis & Perspectives

Get the daily briefing.